The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Myelodysplastic Syndrome: IPSS-Based Risk Stratification and Management

Validated prognostic scoring system guiding treatment decisions in clonal myeloid disorders

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Myelodysplastic Syndrome: IPSS-Based Risk Stratification and Management?

Myelodysplastic syndromes encompass clonal hematopoietic disorders with morphologic dysplasia, peripheral cytopenias and variable risk of acute myeloid leukemia progression.

International Prognostic Scoring System (IPSS) stratifies patients based on bone marrow blast percentage, cytogenetics and number of cytopenias.

Revised IPSS (IPSS-R) provides enhanced prognostic accuracy with five risk categories incorporating refined cytogenetic risk groups and depth of cytopenias.

WHO 2022 classification updates morphologic and genetic categories with emphasis on molecular features including TP53, SF3B1 and other recurrent mutations.

Risk stratification combines IPSS-R, molecular profile, performance status and patient preferences for treatment decision making.

Symptoms

Symptoms of cytopenias including fatigue and dyspnea from anemia, recurrent infections from neutropenia and bleeding or bruising from thrombocytopenia.
Constitutional symptoms with fevers, night sweats, weight loss in some patients particularly with progression.
Splenomegaly may occur in some patients particularly with chronic myelomonocytic leukemia overlap.
Iron overload from chronic transfusion therapy with cardiac, hepatic and endocrine complications.
Symptoms of evolution to acute myeloid leukemia in higher-risk patients with progression.

Risk Factors

Older age with median age at diagnosis approximately 70 years.
Prior cytotoxic therapy including chemotherapy and radiation for previous malignancy (therapy-related MDS).
Environmental exposures including benzene, agricultural chemicals and tobacco smoke.
Inherited bone marrow failure syndromes including Fanconi anemia, dyskeratosis congenita.
Germline predisposition syndromes including DDX41, RUNX1, GATA2 mutations.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent unexplained cytopenias particularly in older adults warrant comprehensive hematologic evaluation.
  • Newly diagnosed MDS requires prompt referral to hematologist for IPSS-R risk stratification and treatment planning.
  • Worsening cytopenias, increasing transfusion requirements or new symptoms in established MDS need reassessment.
  • Symptoms suggesting evolution to acute leukemia including rapid blast count rise require urgent evaluation.
  • Long-term hematologic follow-up is essential for monitoring disease progression and treatment response.

Treatment Methods

01
Lower-risk MDS treatment focuses on supportive care with red cell and platelet transfusions, erythropoiesis-stimulating agents and lenalidomide for del(5q) variant.
02
Hypomethylating agents including azacitidine and decitabine are standard of care for higher-risk MDS providing disease control and survival benefit.
03
Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for selected eligible patients with higher-risk disease.
04
Iron chelation therapy with deferasirox for transfusion-related iron overload in lower-risk patients with adequate life expectancy.
05
Comprehensive multidisciplinary care including risk-adapted treatment selection, infection prophylaxis, supportive transfusions, management of treatment-related complications, clinical trial enrollment and ongoing monitoring optimize outcomes in this heterogeneous disease.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.